Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AMRI Appoints New President, India Operations and New Director of Project Management – Pharmaceutical Services

Published: Monday, October 17, 2011
Last Updated: Monday, October 17, 2011
Bookmark and Share
Mr. Subramanyam Maddala assumes leadership for AMRI’s Indian API manufacturing operations as well as responsibility for AMRI facility operations in Hyderabad and Aurangabad, India.

Reporting to Dr. Steven Hagen, vice president of pharmaceutical development and manufacturing at AMRI, Mr. Maddala brings more than 20 years of operations, business development, and senior leadership experience in the manufacturing of APIs and intermediates, custom synthesis, and formulations in branded and generics markets. Most recently, he served as vice president, Contract Research and Manufacturing Services (CRAMS) and New Generics for Shasun Pharmaceuticals Limited, and was responsible for Shasun’s contract research and manufacturing business, including all vertical CRAMs businesses and new API generic efforts. Prior to that, Mr. Maddala held several roles of increasing responsibility at such firms as Piramal India Limited, Glenmark Pharmaceuticals, Medicorp/Matrix Labs, Torrent Pharmaceuticals, SOL and Lupin Laboratories.

Mr. Maddala earned a Master of Science degree in Applied Chemistry from the University of Baroda, India and a Bachelor of Science degree in Chemistry from Osmania University in Hyderabad, India.

AMRI is also pleased to announce that Dr. Rajesh Shenoy, managing director, AMRI India will be relocating back to the United States to assume the position of director, project management-pharmaceutical services, continuing to report to Dr. Hagen. Dr. Shenoy will have full leadership responsibilities for AMRI’s global project management activities throughout the pharmaceutical services sector, including small scale, large scale, GMP activities, formulations development and manufacturing, and sterile fill and finish. Dr. Shenoy joined AMRI in 1998. He earned a Ph.D. in organic chemistry at the University of Akron and conducted postdoctoral research at Kent State University. Prior to his assignment in India, Dr. Shenoy held positions of increasing responsibility in AMRI’s discovery and development services operations.

“We are pleased to welcome Mr. Maddala to the AMRI leadership team and believe he is the right person to take AMRI’s chemical manufacturing business in India to the next level, including the capability to eventually manufacture multiple products in India to U.S. FDA standards.” Dr. Hagen continued, “Dr. Shenoy’s return to the United States caps a six-year assignment in which he established, built, and oversaw AMRI’s Hyderabad laboratory operations, eventually assuming leadership for all of our country operations in India, including our manufacturing activities in Aurangabad. We appreciate his continued contributions to AMRI and wish them both great successes in their new roles.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Wednesday, December 16, 2015
AMRI, PerkinElmer to Collaborate on Drug Discovery
Albany Molecular Research (AMRI) and PerkinElmer are collaborating to provide drug discovery infrastructure and services in AMRI's newly launched drug discovery center.
Thursday, June 18, 2015
AMRI to Close Holywell, U.K. API Manufacturing Facility
Company plans to cease operations at the site by the end of 2015.
Thursday, April 09, 2015
AMRI Proposes To Close UK-Based API Manufacturing Facility
The proposed closure would affect approximately 64 positions.
Friday, February 20, 2015
AMRI Announces CFO Transition
Michael M. Nolan, senior vice president and chief financial officer, will be departing AMRI.
Thursday, January 15, 2015
AMRI To Acquire Aptuit Drug Product Development Businesses
Significantly expands AMRI's analytical services capabilities and extends drug product development services to include sterile injectable formulation development.
Friday, January 09, 2015
AMRI to Acquire Oso Biopharmaceuticals Manufacturing
Acquisition significantly expands contract manufacturing capabilities to include commercial scale sterile injectables.
Tuesday, June 03, 2014
AMRI to Acquire Cedarburg Pharmaceuticals, Inc.
Broadens contract development and manufacturing capabilities with high value, complex API business.
Friday, March 28, 2014
AMRI Announces Senior Level Leadership Appointment
The appointment of Michael A. Luther, Ph.D. as Senior Vice President of Discovery sees AMRI expanding its biology capabilities.
Thursday, October 17, 2013
AMRI Awarded Contract from the UK Government
Seven-year contract awarded for the development and manufacture of an active ingredient under clinical evaluation.
Thursday, October 03, 2013
FDA Performs Re-inspection of AMRI Burlington MA Facility
Issues Form 483 for three inspectional observations.
Friday, July 26, 2013
AMRI Burlington Receives DEA Approval to Handle Controlled Substances
Approval to handle Schedule 2 and 2N controlled substances at this location further supports AMRI SMARTSOURCING™ offering.
Wednesday, June 19, 2013
AMRI Promotes Susan Collins to Director, Business Development
Ms. Collins is responsible for leading AMRI’s North American Discovery Business Development team.
Tuesday, June 18, 2013
AMRI Announces Appointment of Chairman of the Board of Directors
Company has appointed William S. Marth as Chairman of the Board, effective June 5, 2013.
Friday, June 07, 2013
AMRI and Ono Broaden SMARTSOURCING™ Collaboration
New agreement extends drug discovery and development collaboration between the companies.
Friday, April 26, 2013
Scientific News
Head Injury Patients have Protein Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
Exposure to Air Pollution 30 Years Ago Associated with Increased Risk of Death
Exposure to air pollution more than 30 years ago may still affect an individual's mortality risk today, according to new research from Imperial College London.
More Then 1 in 20 U.S. Children have Dizziness and Balance Problems
Researchers at NIH have found that girls have a higher prevalence of dizziness and balance problems compared to boys, 5.7 percent and 5.0 percent.
Biosensors on Demand
New strategy results in custom "designer proteins" for sensing a variety of molecules.
Low-Cost, Portable NQR Spectroscopy
A researcher at Case Western Reserve University is developing a low-cost, portable prototype designed to detect tainted medicines and food supplements that otherwise can make their way to consumers. The technology can authenticate good medicines and supplements.
Structure of Brain Plaques in Huntington's
Researchers at the University of Pittsburgh School of Medicine have shown that the core of the protein clumps found in the brains of people with Huntington's disease have a distinctive structure, a finding that could shed light on the molecular mechanisms underlying the neurodegenerative disorder.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Unique Mechanism for a High-Risk Leukemia
Researchers uncovered the aberrant mechanism underlying a notoriously treatment-resistant acute lymphoblastic leukemia subtype; findings offer lessons for understanding all cancers.
Visualizing a Cancer Drug Target at Atomic Resolution
Using cryo-electron microscopy, researchers were able to view, in atomic detail, the binding of a potential small molecule drug to a key protein in cancer cells.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!